[1] |
WANG Ruyue, XIE Fei, WANG Xin, LI Hongyu.
Therapeutic effect of lienal polypeptide injection on bone marrow suppression and immunodeficiency in KM mice following chemotherapy
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1000-1007.
|
[2] |
JIANG Daoli, CHOU Xiaohua, LIU Zhidong, LI Wei, ZHANG Bo, XU Sang, TAN Defei, FANG Yi, LV Dongmei, WANG Tao.
Real-world study of ceftazidime-avibactam in the treatment of multidrug-resistant gram-negative bacterial infections
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1008-1017.
|
[3] |
WANG Fei, HANG Yongfu, WANG Wei.
Influence of argumented renal clearance on teicoplannin serum concentrations in critical ill patients
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1043-1048.
|
[4] |
HE Lihua, ZHU Xiuzhi, JIANG Yizhou.
Research progress on immunotherapy for triple-negative breast cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 842-853.
|
[5] |
ZHANG Huyunlong, ZHU Xiuzhi, JIN Xi, SHAO Zhimin.
Mechanisms of endocrine-resistance and therapeutic breakthroughs in hormone receptor-positive, HER2-negative breast cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 854-865.
|
[6] |
LUO Shiping, ZHANG Jie, YU Yushuai, SONG Chuangui.
Advances in targeted therapy for HER2-positive breast cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 876-886.
|
[7] |
XIANG Yimei, ZHANG Ningning, HUANG Yuxin, ZENG Xiaohua.
Research progress of biomarkers related to the efficacy of HER2 positive breast cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 887-897.
|
[8] |
CHEN Keyu, HUANG Yuan, WANG Xiaojia, ZHENG Yabing.
Clinical application and research progress of antibody drugs conjugation in breast cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 898-909.
|
[9] |
CHEN Qun, ZHU Heping, YUAN Xiaolong.
Analysis of 197 cases of pentoxifylline injection and exploring supervision mode of rational drug use in hospitals
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 948-953.
|
[10] |
LIU Min, KONG Xiang, ZHANG Ye, GU Yifei, XIANG Xuemei, HE Qing, HUANG Kai.
Analysis of reasons for screening failure of healthy subjects in clinical trials of orally inhaled drug products
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 758-766.
|
[11] |
HOU Qiong, LIU Fei, CHEN Chuanrong.
Immunotherapy combined with anti-angiogenic drugs and chemotherapy in negative driver gene and advanced non-small cell lung cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 775-779.
|
[12] |
WANG Lin, YU Jianguo, LI Xiao, LUAN Jiajie.
Establish and implement a pre-prescription system for outpatient based on Six Sigma DMAIC model
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 780-787.
|
[13] |
YU Qiaoling, ZHAI Weiwei, LIU Ping, QIU Bo, WU Huizhen.
Research progress in plasma concentration monitoring of rivaroxaban
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 809-817.
|
[14] |
LI Qinghua, ZHAO Yan, ZHAO Haigang, GAO Pengfei, XU Bingxin.
Value of ABCB1 G2677T gene polymorphism detection in lipid-lowering therapy with atorvastatin in patients suffered from ischemic stroke
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 633-640.
|
[15] |
QIAO Hongliang, DING Ning, DENG Kaihong, LIU Binbin, DONG Chuanjiang, CHEN Xiaobo, ZOU Lili.
New progress in research on novel control strategies for methicillin-resistant staphylococcus aureus infection
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 676-687.
|